Portal de Periódicos da CAPES

Causes of Neuroleptic Noncompliance

1986; Slack Incorporated (United States); Volume: 16; Issue: 10 Linguagem: Inglês

10.3928/0048-5713-19861001-07

1938-2456

Peter J. Weiden, Eric Shaw, J. John Mann,

Cardiovascular Syncope and Autonomic Disorders

Maintenance Psychotropic Medications and ComplianceCauses of Neuroleptic Noncompliance Peter J Weiden, MD, , , MD Eric Shaw, PhD, , and , PhD J John Mann, MD, , MD Peter J Weiden, MD , Eric Shaw, PhD , and J John Mann, MD Psychiatric Annals, 2013;16(10):571–575Published Online:October 01, 1986https://doi.org/10.3928/0048-5713-19861001-07Cited by:46View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1 Blackwell B: Treatment adherence. Br J Psychiatry 1976; 129:513-531. > Google Scholar2. Appelbaum PS, Guiheil TG: Clinical aspects of treatment refusal. Compi- Psychialry 1982; 23:560-566. > Google Scholar3. Nelson AA. Gold BH. Hutchinson RA. et al: Drug default among schizophrenic patients. Am J Hasp Pharm 1975; 32:1237-242. > Google Scholar4. McEvuy JP. Howe AC, Hogarty GE: Differences in the nature of relapse and subsequent inpatient course between medication compliant and noncompliant schizophrenic patients. J New Ment Dis 1984; 172:412-416. > Google Scholar5. Weiden PJ, Mann JJ: Extrapyramidal reactions, neuroleptic-induced dysphoria and clinical outcome: New research. American Psychiatric Associalion Annual Meeting. Dallas, Texas, May 18-24. 1985. > Google Scholar6. Carpenter WT. Heinrichs DW, Alphas LD: Treatment of negative symptoms. Schizophr Hull 1985; 11:441-452. > Google Scholar7. Henninger G, DiMascio A. Klemian GL: Personality factors in variability of response to phenothiazines. Am J Psychiatry 1965; 121:1091-1094. > Google Scholar8. Gillick MR: Common-sense models of health and disease. N Engl J Med 1985; M5-.7000-703. > Google Scholar9. Irwin DS. Weitzell WD, Morgan DW: Phenothiazine intake and staff attitudes. Am J Psychiatry 1971; 127:1631-1635. > Google Scholar10. Shapiro AK. Morris LA: The placebo effect in medical and psychological therapies, in Gargield SL, Bcrgin AE (eds): Handbook of Psychotherapy and Behavioral Change: An Empirical Analysis. New York. |ohn Wiley & Sons. 1978. > Google Scholar11 . Diamond R : Drugs and the quality of life: The patient's point of view, f Clin Psychiatry 1985; 46:29-35. > Google Scholar12. Tarsy D: Movement disorder with neuroleptic drug treatment. Psychiatr Clin North Am 1984; 7:453-471. > Google Scholar13. Van Pulten T: Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31:67-72. > Google Scholar14. Alexopoulos GS: Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis 1979; 167:125-127. > Google Scholar15. Muneiz MR. Roth LH: Informing patients about tardive dyskinesia. Arch Gen Psychiatry 1985; 42:866-871. > Google Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Hoertnagl C, Kaufmann A, Yalcin-Siedentopf N, Pfaffenberger N, Frajo-Apor B, Pardeller S, Kemmler G and Hofer A (2020) Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With Schizophrenia, Frontiers in Psychiatry, 10.3389/fpsyt.2020.570857, 11 Barnes T and Haddad P (2020) Working with People with Mental Health Difficulties to Improve Adherence to Medication The Wiley Handbook of Healthcare Treatment Engagement, 10.1002/9781119129530.ch23, (430-454), Online publication date: 6-Feb-2020. Brown E and Gray R (2015) Tackling medication non-adherence in severe mental illness: where are we going wrong?, Journal of Psychiatric and Mental Health Nursing, 10.1111/jpm.12186, 22:3, (192-198), Online publication date: 1-Apr-2015. Vita A, Barlati S and Sacchetti E (2014) Non-Pharmacological Strategies to Enhance Adherence and Continuity of Care in Schizophrenia Adherence to Antipsychotics in Schizophrenia, 10.1007/978-88-470-2679-7_3, (99-137), . (2012) The management of negative symptoms Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition, 10.3109/9781842145357-4, (47-58), Online publication date: 20-Sep-2012. Copolov D and Castle D (2012) The management of negative symptoms Pharmacological and Psychosocial Treatments in Schizophrenia, 10.3109/9781842145357.003, (47-58), Online publication date: 1-May-2012. Barkhof E, Meijer C, de Sonneville L, Linszen D and de Haan L (2020) Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–A review of the past decade, European Psychiatry, 10.1016/j.eurpsy.2011.02.005, 27:1, (9-18), Online publication date: 1-Jan-2012. Janicak P (2011) In This Issue: Treatment Challenges of Schizophrenia, Psychiatric Annals, 41:5, (246-247), Online publication date: 1-May-2011. Razali S (2010) Prevention of relapse and interventions for enhancing medication adherence in schizophrenia: An East Asian perspective, Asia-Pacific Psychiatry, 10.1111/j.1758-5872.2010.00067.x, 2:2, (68-76) (2008) Management of Negative Symptoms Pharmacological and Psychosocial Treatments in Schizophrenia, 10.3109/9780203091579-4, (35-45), Online publication date: 1-Jan-2008. Hofer A, Rettenbacher M, Widschwendter C, Kemmler G, Hummer M and Fleischhacker W (2005) Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder, European Archives of Psychiatry and Clinical Neuroscience, 10.1007/s00406-005-0633-3, 256:4, (246-255), Online publication date: 1-Jun-2006. Haro J and Salvador-Carulla L (2006) The SOHO (Schizophrenia Outpatient Health Outcome) Study, CNS Drugs, 10.2165/00023210-200620040-00003, 20:4, (293-301), . Pogge D, Singer M and Harvey P (2005) Rates and Predictors of Adherence with Atypical Antipsychotic Medication: AFollow-Up Study of Adolescent Inpatients, Journal of Child and Adolescent Psychopharmacology, 10.1089/cap.2005.15.901, 15:6, (901-912), Online publication date: 1-Dec-2005. Kikkert M, Schene A, Koeter M, Robson D, Born A, Helm H, Nose M, Goss C, Thornicroft G and Gray R (2005) Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views, Schizophrenia Bulletin, 10.1093/schbul/sbl011, 32:4, (786-794) Chue P (2014) Compliance and convenience: do physicians and patients see depot medication differently?, Acta Neuropsychiatrica, 10.1111/j.0924-2708.2004.00099.x, 16:6, (314-318), Online publication date: 1-Dec-2004. Cortese L, Jog M, McAuley T, Kotteda V and Costa G (2004) Assessing and Monitoring Antipsychotic-Induced Movement Disorders in Hospitalized Patients: A Cautionary Study, The Canadian Journal of Psychiatry, 10.1177/070674370404900105, 49:1, (31-36), Online publication date: 1-Jan-2004. Wright P, Lindborg S, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor C, Roth J, Battaglia J, Bitter I, Chouinard G, Morris P and Breier A (2016) Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment, The Canadian Journal of Psychiatry, 10.1177/070674370304801102, 48:11, (716-721), Online publication date: 1-Dec-2003. Castle D and Gilbert M (2003) The Scope for Psychosocial Treatments for Psychosis, Psychiatry, Psychology and Law, 10.1375/pplt.2003.10.1.149, 10:1, (149-153), Online publication date: 1-Jun-2003. Gournay K and Gray R (2016) Mental health nurse prescribing: The research challenge, NT Research, 10.1177/136140960300800303, 8:3, (173-184), Online publication date: 1-May-2003. Bobes J, Gibert J, Ciudad A, Alvarez E, Cañas F, Carrasco J, Gascón J, Gómez J and Gutiérrez M (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/S0278-5846(03)00035-6, 27:3, (473-481), Online publication date: 1-May-2003. Haro J, Edgell E, Jones P, Alonso J, Gavart S, Gregor K, Wright P and Knapp M (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment, Acta Psychiatrica Scandinavica, 10.1034/j.1600-0447.2003.00064.x, 107:3, (222-232), Online publication date: 1-Mar-2003. Alvarez E, Bobes J, Gómez J, Sacristán J, Cañas F, Carrasco J, Gascón J, Gibert J and Gutiérrez M (2003) Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study, European Neuropsychopharmacology, 10.1016/S0924-977X(02)00079-2, 13:1, (39-48), Online publication date: 1-Jan-2003. Gray R, Wykes T and Gournay K (2002) From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication, Journal of Psychiatric and Mental Health Nursing, 10.1046/j.1365-2850.2002.00474.x, 9:3, (277-284), Online publication date: 1-Jun-2002. Costa e Silva J, Alvarez N, Mazzotti G, Gattaz W, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor C, Wang J and Tran P (2001) Olanzapine as Alternative Therapy for Patients With Haloperidol-Induced Extrapyramidal Symptoms: Results of a Multicenter, Collaborative Trial in Latin America, Journal of Clinical Psychopharmacology, 10.1097/00004714-200108000-00004, 21:4, (375-381), Online publication date: 1-Aug-2001. Gray R, Wykes T, Parr A, Hails E and Gournay K (2001) The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice, Journal of Psychiatric and Mental Health Nursing, 10.1046/j.1365-2850.2001.00377.x, 8:3, (191-196), Online publication date: 1-Jun-2001. Tohen M, Zhang F, Taylor C, Burns P, Zarate C, Sanger T and Tollefson G (2001) A meta-analysis of the use of typical antipsychotic agents in bipolar disorder, Journal of Affective Disorders, 10.1016/S0165-0327(00)00162-2, 65:1, (85-93), Online publication date: 1-Jun-2001. SECKINGER R and AMADOR X (2001) Cognitive-Behavioral Therapy in Schizophrenia, Journal of Psychiatric Practice, 10.1097/00131746-200105000-00005, 7:3, (173-184), Online publication date: 1-May-2001. Tollefson G, Birkett M, Kiesler G and Wood A (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine, Biological Psychiatry, 10.1016/S0006-3223(00)01026-X, 49:1, (52-63), Online publication date: 1-Jan-2001. Tollefson G and Taylor C (2006) Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent, CNS Drug Reviews, 10.1111/j.1527-3458.2000.tb00155.x, 6:4, (303-363) Gray R and Gournay K (2001) What can we do about acute extrapyramidal symptoms?, Journal of Psychiatric and Mental Health Nursing, 10.1046/j.1365-2850.2000.00296.x, 7:3, (205-211), Online publication date: 1-Jun-2000. Masand P (2005) Weight gain associated with psychotropic drugs, Expert Opinion on Pharmacotherapy, 10.1517/14656566.1.3.377, 1:3, (377-389), Online publication date: 1-Mar-2000. Copolov D (2016) Hubris and Humility in the Life of the Schizophrenia Researcher, Australian & New Zealand Journal of Psychiatry, 10.1046/j.1440-1614.1999.00569.x, 33:3, (299-306), Online publication date: 1-Jun-1999. Falsetti A (2017) Olanzapine: Psychopharmacology, Clinical Efficacy, and Adverse Effects, Hospital Pharmacy, 10.1177/001857879903400407, 34:4, (423-436), Online publication date: 1-Apr-1999. Hellewell J, Kalali A, Langham S, McKellar J and Awad A (2009) Patient satisfaction and acceptability of long-term treatment with quetiapine, International Journal of Psychiatry in Clinical Practice, 10.3109/13651509909024770, 3:2, (105-113), Online publication date: 1-Jan-1999. Sair A, Bhui K, Haq S and Strathdee G (2018) Improving treatment adherence among patients with chronic psychoses, Psychiatric Bulletin, 10.1192/pb.22.2.77, 22:2, (77-81), Online publication date: 1-Feb-1998. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C and Tollefson G (1997) Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders, Journal of Clinical Psychopharmacology, 10.1097/00004714-199710000-00010, 17:5, (407-418), Online publication date: 1-Oct-1997. &NA; (1996) The Impact of Individualized Consultation and Group Workshop Family Education Interventions on III Relative Outcomes, The Journal of Nervous and Mental Disease, 10.1097/00005053-199604000-00009, 184:4, (252-254), Online publication date: 1-Apr-1996. Pantelis C and Barnes T (2016) Drug Strategies and Treatment-Resistant Schizophrenia, Australian & New Zealand Journal of Psychiatry, 10.3109/00048679609076070, 30:1, (20-37), Online publication date: 1-Feb-1996. Meltzer H (2020) Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine, European Psychiatry, 10.1016/0767-399X(96)80080-0, 10:S1, (19s-25s), . Bowen J and Barnes T (1994) The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of antipsychotic medication, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.470090605, 9:6, (423-433), Online publication date: 1-Nov-1994. Sellwood W and Tarrier N (1994) Demographic factors associated with extreme non-compliance in schizophrenia, Social Psychiatry and Psychiatric Epidemiology, 10.1007/BF00802014, 29:4, (172-177), Online publication date: 1-Jul-1994. Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome, Acta Psychiatrica Scandinavica, 10.1111/j.1600-0447.1994.tb05825.x, 89:s380, (8-13), Online publication date: 1-May-1994. Sanua V (1994) Quo vadis APA? Inroads of the medical model., The Humanistic Psychologist, 10.1080/08873267.1994.9976933, 22:1, (3-27) Murphy M and Moller M (1993) Relapse management in neurobiological disorders: The Moller-Murphy Symptom Management Assessment Tool, Archives of Psychiatric Nursing, 10.1016/0883-9417(93)90031-Q, 7:4, (226-235), Online publication date: 1-Aug-1993. Weiden P, Mann J, Dixon L, Haas G, DeChillo N and Frances A (1989) Is neuroleptic dysphoria a healthy response?, Comprehensive Psychiatry, 10.1016/0010-440X(89)90085-0, 30:6, (546-552), Online publication date: 1-Nov-1989. Mercier C (1989) Le rôle des facteurs subjectifs dans la fidélité à la médication * , The Canadian Journal of Psychiatry, 10.1177/070674378903400707, 34:7, (662-667), Online publication date: 1-Oct-1989. Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 6.5 MB Published online10/01/86